ANTHONY C. CHANG, M.D., F.A.C.C., F.A.C.P, F.A.W.M.

Virginia Heart, P.C.

2901 Telestar Ct. #200

Falls Church, VA 22042

 

EDUCATION

August 1982 - May 1986; M.D., University of Texas/Southwestern Medical School, Dallas, Texas

August 1979 - April 1982; University of Texas, Arlington, TX. Major: Biochemistry

 

PRIVATE PRACTICE

July 1, 1992- June 1996 Larry Jackson, M.D.

1830 Town Center Drive, #408

Reston, VA 22090

June 10, 1996 - Present Virginia Heart

2901 Telestar Ct. #200

Falls Church, VA 22042

 

POSTGRADUATE TRAINING

Indiana University Medical Center, Indianapolis, Indiana

July 1986 - June 1988, Internship and Residency - Internal Medicine

 

Cardiology Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland

July 1988 - June 1990, Fellowship in Cardiology

 

Cardiology Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland

July 1990 - December 1990, Cardiology and Cardiac Surgery Ward Chief

St. Vincent Hospital, Electrophysiology Laboratory, Indianapolis, Indiana

January 1991 - June 1991, Fellowship in Cardiac Electrophysiology

Director: Dr. Eric N. Prystowsky

 

Cardiology Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland

July 1991 - June 1992, Senior Fellow in Cardiac Electrophysiology

 

Bethesda Naval Hospital, National Naval Medical Center, Bethesda, Maryland

February 1992 - March 1992, Clinical Fellow in Cardiology

 

LICENSURE

State of Virginia - 0101047816

 

CERTIFICATION

September 13, 1989 - Internal Medicine, American Board of Internal Medicine

November 6, 1991 - Cardiovascular Disease (Recertified May 2001, 2011)

November 10, 1994 - Clinical Cardiac Electrophysiology (Recertified Nov 2004, 2014)

September 20, 1993 - Tetamur, NASPExAM (Special competency in cardiac pacing)

Basic Life Support, currently certified

Advanced Cardiac Life support, currently certified

Advance Wilderness Life Support, currently certified

 

HOSPITAL AFFILIATIONS

Inova Alexandria Hospital, Alexandria, Virginia

Virginia Hospital Center, Arlington, Virginia

Inova Fairfax Hospital, Fairfax, Virginia

Inova Fair Oaks Hospital, Fairfax, Virginia

Reston Hospital Center, Reston, Virginia

Inova Loudoun Hospital, Leesburg, Virginia

 

OTHER APPOINTMENTS

July 1992 - June 1996, Research Associate

Cardiac Electrophysiology Laboratory and Inherited Cardiovascular Disease

Section, Cardiology Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland

 

February 1996 - 2004, Consultant to the Circulatory System Device Panel

Center for Devices & Radiological Health, Division of Cardiovascular,

Respiratory & Neurological Devices, Food and Drug Administration

 

PROFESSIONAL MEMBERSHIPS

American College of Cardiology (Fellow)

American College of Physicians (Fellow)

Academy of Wilderness Medicine (Fellow)

Heart Rhythm Society (Member)

Wilderness Medicine Society (Member)

UNIFORMED SERVICE

October 1989 - 1996, United States Public Health Service, Research Corp

 

FOREIGN LANGUAGES

Chinese

 

RESEARCH

Principal Investigator

Pacesetter Steroid Tined Lead Clinical Evaluation

 

SHIELD 2.   A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients with an Implantable Cardioverter Defibrillator.

 

TEMPO: Phase 2, Randomized, Placebo controlled, Dose ranging, parallel group study to Evaluate the effect of GS-6615 on ventricular arrhythmia in subject with ICD or CRT-D.

 

ARTESIA: Apixaban for the Reduction of Thrombo-Embolism in patients with

Device-Detected Sub-Clinical Atrial fibrillation

 

Sub-Investigator

 

VALUE Trial: Phase IIIB/IV multicenter, multinational, double blind, randomized active controlled trial to compare the effect of valsartan with or without the addition of HCTZ on cardiovascular morbidity and mortality in patients with essential hypertension.

 

A.L.I.V.E.: Azimilide Post Infarct Survival Evaluation Trial. A double-blind, placebo-controlled, parallel design study to determine the effect of 75 or 100mg. of orally administered azimilide dihydrochloride versus placebo on survival in recent post-myocardial infarction patients at risk of sudden death.

 

COMPANION: (Comparison of Medical Therapy, Pacing, And Defibrillation In Heart Failure)

Multicenter randomized controlled trial designed to determine whether combined all-cause mortality and hospitalization in heart failure patients receiving optimal pharmacologic therapy (OPT) can be reduced by combining OPT and 1) biventricular pacing therapy alone or 2) biventricular pacing with defibrillation.

 

SHIELD: (SHock Inhibition Evaluation with AzimiLiDe) A Multi-center, 12-month, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of 75 and 125 mg Doses of Oral Azimilide Dihydrochloride in Patients with an Implantable Cardioverter Defibrillator for  the treatment of Ventricular Arrythmia

 

ST JUDE ACT Registry: Data collection, outcome-oriented registry of all patients implanted with a St. Jude ICD.  Secondary aim is to evaluate the programming and application of advanced features on ICD therapy in patients with St. Jude ICD.

 

PARTNERS HF:  Multi-site Program to Access and Review Trending Information and Evaluate CoRrelation to Symptoms in Patients with Heart Failure

 

PROVE:  Data collection study. Programming Ventricular Tachycardia Therapy in patients with a primary prevention implantable cardioverter-defibrillator indication.

 

REDUCE: Data collection study.  To Evaluate the Effectiveness of Ventricular Pacing in Dual Chamber ICD using AutoIntrinsic Conduction Search.

 

ENSURE CRT: Study-post market Medtronic cardiac resynchronization therapy study.  Data collection study to evaluate how physicians programming preference affect the amount of CRT patients receive

 

REFLEx Study:  Post market study by Guidant comparing the efficacy of defibrillation leads

 

CONNECT Study: Post market study by Medtronic to evaluate the clinical benefit of remote management features to clinicians and patients.

 

OPTIMUM: Registry designed to evaluate the Optimim Lead by St. Jude.

 

RATE: Registry by St. Jude Medical to produce a prospective, outcome oriented data collection registry on the prevalence of AT/AF and its effect on the general CRM population.

 

ROCKET AF: Randomized study to evaluate the efficacy and safety of a novel anticoagulation agent.

 

SYSTEM LOGNEVITY STUDY (SLS): A prospective, non randomized study of implanted commercially available cardiac therapy products. Primary purpose is to evaluate and publish the long term reliability and performance of Medtronic market released cardiac therapy products.